Background -Nebulised frusemide has been shown to be protective against bronchoconstricting stimuli in adult asthmatic subjects and against cold air challenge in children. Animal studies suggest that inhaled frusemide may be more effective in the young. Methods -A double blind placebo, controlled, crossover study on the effect on exercise of pretreatment with frusemide (20 mg) from a metered dose inhaler via a large volume spacer (Volumatic) was performed in 12 asthmatic children. Exercise testing consisted of eight minutes of running on a treadmill in an environmentally controlled laboratory. Results -Deterioration in lung function was less after frusemide than after the placebo exercise tests. The mean (95% CI) maximum percentage falls in forced expiratory volume in one second (FEV,) were 14-4% (7.7 to 21-0) for placebo and 5*7% (2.3 to 9.0) for frusemide. Conclusions -Inhaled frusemide via a metered dose inhaler reduces exerciseinduced bronchoconstriction in children. (Thorax 1995;50:677-679) Keywords: asthma, children, frusemide. 
Nebulised (but not intravenous or oral) frusemide has been shown in adult asthmatic subjects to be protective against bronchoconstriction induced by allergen,' exercise,2 ultrasonically nebulised water,3 and nebulised sodium metabisulphite.4 Nebulised frusemide also protects against cold air-induced bronchoconstriction in children with mild to moderate asthma.5
Animal studies suggest a more pronounced effect and a longer duration of action of frusemide in newborn than in adult guinea pigs6; there is therefore a need for studies in children to establish its protective profile.
Methods

SUBJECTS
Twelve patients (eight boys) aged 7-14 years (mean 10-6 years) were recruited from the asthma clinic of the Royal Brompton Hospital. Patients were recruited if they complained of exercise-induced asthma and agreed to participate in the study. Asthma was diagnosed on the basis of both a clinical history of intermittent respiratory symptoms and either a peak flow lability of 20% or an improvement in forced expiratory flow in one second (FEV,) U.
Placebo Frus placebo 14-4% (7 7 to 21.0), frusemide 5-7% (2-3 to 9-0). The results for the control and placebo days were not statistically different, while the results for the frusemide day were statistically different from both the control and placebo days (p=0 005). Thus, the degree of protection afforded by frusemide (calculated as the differences in changes of lung function after placebo and frusemide expressed as percentage of the change after placebo) was 60%. The mean (95% confidence intervals) maximal percentage falls in PEFR were: control 18A4% (13-2 to 23 6), placebo 21-1% (12-0 to 30 2), frusemide 12-5% (7.7 to 17.2). The differences with frusemide treatment did not reach statistical significance. There was no statistically significant difference between mean maximal percentage falls in FEF2, 75. We have investigated the safety and tolerability of the salmeterol/HFA134a inhaler in healthy subjects and compared its systemic pharmacodynamic activity with that of the current salmeterol inhaler using chlorofluorocarbon propellant 1 1 and 12 (P 1 1/P 1 2).
Methods
Twelve healthy men of mean age 26-9 years (range and mean weight 76 1 kg (range 59-92) gave their written informed consent. The study was approved by the local ethics committee and carried out in accordance with the provisions of the Declaration of Helsinki and later revisions.
Subjects received the salmeterol/HFA134a inhaler, the salmeterol/P 1 /12 inhaler, and placebo (HFA134a) in a double blind, randomised, three-way crossover manner on three different days at least one week apart. Salmeterol doses were cumulative: 50, 50, 100,
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